An announcement from Myriad Genetics (MYGN) is now available.
Myriad Genetics, Inc. has reported promising initial findings from a study suggesting that GeneSight testing may reduce hospitalizations by up to 39%. However, a follow-up analysis to establish a causal link through a control group has been deemed unreliable due to disparities in baseline data, leading the company to abandon this part of the study. More comprehensive results are expected to be published later as the research progresses.
For detailed information about MYGN stock, go to TipRanks’ Stock Analysis page.
